- RET inhibitor and pharmaceutical composition and application thereof
-
The invention belongs to the field of medicines, and relates to an RET inhibitor and a pharmaceutical composition and application thereof. Specifically, the invention relates to a compound as shown in a formula (I), or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug of the compound as shown in the formula (I). The invention also relates to pharmaceutical compositions comprising the compounds, and uses of the compounds and pharmaceutical compositions thereof in the preparation of a medicine which is especially used for the treatment and prevention of RET-related diseases and disorders, including cancers, irritable bowel syndrome and/or pain associated with irritable bowel syndrome.
- -
-
Paragraph 0356-0359
(2021/10/27)
-
- SUBSTITUENT-INCLUDING UREA COMPOUND
-
An object of the present invention is to provide a compound that has a specific chemical structure having an activation effect on SIRT6 and is useful as an active component for preventing and treating inflammatory diseases. The present invention relates to a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof. (Each symbol in Formula (1) has the same definition as that described in the specification.)
- -
-
Paragraph 0580-0583
(2021/12/03)
-
- HETEROARYLTHIOMETHYL PYRIDINE DERIVATIVE
-
The present invention relates to a compound represented by a formula (I): wherein X is a group represented by or the like; Y is a group represented by or the like; and Ar1 is a group represented by or a pharmaceutically acceptable salt thereof.
- -
-
Page/Page column 38
(2010/11/17)
-
- SPIRO CONDENSED PIPERIDNES AS MODULATORS OF MUSCARINIC RECEPTORS
-
The present invention relates to modulators of muscarnic receptors of formula (I). The present invention also provides impositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.
- -
-
Page/Page column 47
(2008/06/13)
-
- MODULATORS OF MUSCARINIC RECEPTORS
-
The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.
- -
-
Page/Page column 84
(2010/10/20)
-
- MODULATORS OF MUSCARINIC RECEPTORS
-
The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.
- -
-
Page/Page column 70
(2010/11/08)
-
- 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS
-
The present invention provides compounds of Formula (I) Wherein ( ) is an optional ethylene bridge; R1 is alkyl, cycloalkyl, aryl or aryl substituted with one or more substituents selected from alkyl, alkoxy and amino, or R1 is pyridyl or pyridyl substitu
- -
-
-
- Bridged bicyclic amine derivatives useful as CCR-3 receptor antagonists
-
Compounds having the formula (I), Ar—(F)(E)-(CR3R4)—(CHR5)m-(T)-(Q)-Ar1, are useful as CCR-3 receptor antagonists, wherein T is a bridged heterocyclyl group having one N atom and a bridge of one to two bridgehead carbon atoms; Ar and Ar1 are aryl or heteroaryl; F is alkylene, alkenylene, or a bond; E is —C(═O)N(R10)—, —SO2N(R10)—, —N(R11)C(═O)N(R10O)—, —N(R11)SO2N(R10)—, —N(R11)C(═S)N(R10)—, —N(R11)C(═O)—, —N(R11)SO2—, —N(R12)C(═O)CH(R13)—, or CH(R13)C(═O)N(R12)—; Q is —C(═O)— or C1-2alkylene; and R3, R4, R5, R9, R10, R11, R12, and R13 are defined as set forth in the specification.
- -
-
Page/Page column 9
(2010/02/08)
-
- Substituted bridged phenyl piperidines: Orally active growth hormone secretagogues
-
A new series of growth hormone secretagogues have been discovered. The best compound, 26j, shows excellent ability to release growth hormone both in vitro and in vivo. The synthesis and biological activity of these compounds are discussed.
- Lu, Zhijian,Tata, James R.,Cheng, Kang,Wei, Liente,Chan, Wanda W.-S.,Butler, Bridget,Schleim, Klaus D.,Jacks, Thomas M.,Hickey, Gerard,Patchett, Arthur A.
-
p. 1817 - 1820
(2007/10/03)
-